噻托溴铵联合布地奈德福莫特罗治疗成人重度支气管哮喘的临床观察

发布时间：2018-03-30 12:05

本文选题：噻托溴铵　切入点：布地奈德福莫特罗　出处：《中国药房》2017年23期

【摘要】：目的:观察噻托溴铵联合布地奈德福莫特罗治疗成人重度支气管哮喘的临床疗效及安全性。方法:选取我院2013年3月-2016年3月收治的重度支气管哮喘成年患者共110例,按随机数字表法分为对照组和观察组,各55例。对照组患者给予布地奈德福莫特罗粉吸入剂,每次2吸,bid;观察组患者在对照组基础上加用噻托溴铵粉吸入剂18μg,qd。两组患者均治疗6个月。比较两组患者的临床疗效,治疗前后的哮喘控制测试表(ACT)评分、呼吸功能指标和哮喘急性发作次数,以及不良反应发生情况。结果:观察组患者的显效率和总有效率分别为54.55%、96.36%,均显著高于对照组的32.73%、78.18%,差异均有统计学意义(P0.05)。治疗前,两组患者的ACT评分、各呼吸功能指标和哮喘急性发作次数比较,差异均无统计学意义(P0.05);治疗后,两组患者的ACT评分显著高于治疗前,1秒用力呼气容积(FEV1)、FEV1占用力肺活量的比值和最大呼气流量均显著大于治疗前,最大呼气流量变异率显著低于治疗前,且观察组各指标均显著优于对照组,差异均有统计学意义(P0.05);治疗后1、3、6个月时,两组患者的哮喘急性发作次数均显著少于治疗前,且观察组发作次数均显著少于同期对照组,差异均有统计学意义(P0.05)。观察组患者的不良反应发生率为20.00%,与对照组的14.55%比较,差异无统计学意义(P0.05)。结论:噻托溴铵联合布地奈德福莫特罗治疗成人重度支气管哮喘可有效降低病情严重程度,改善患者呼吸功能,减少哮喘急性发作次数,临床疗效好且安全性较高。
[Abstract]:Objective: to observe the efficacy and safety of tiotropium bromide combined with budesonide formoterol in the treatment of adult severe bronchial asthma.Methods: 110 adult patients with severe bronchial asthma admitted in our hospital from March 2013 to March 2016 were randomly divided into control group (55 cases) and observation group (55 cases).The patients in the control group were given budesonide formoterol powder inhalation for 2 times, and the patients in the observation group were given tiotropium bromide powder inhaler 18 渭 g QD on the basis of the control group.Both groups were treated for 6 months.The clinical efficacy, ACT score, respiratory function index, acute attack times and adverse reactions were compared between the two groups before and after treatment.Results: the effective rate and the total effective rate of the patients in the observation group were 54.55 and 96.36, respectively, which were significantly higher than that in the control group (32.73 and 78.18, respectively), and the difference was statistically significant (P 0.05).Before treatment, there was no significant difference in ACT score, respiratory function index and acute attack frequency of asthma between the two groups (P 0.05).The ACT score of the two groups was significantly higher than that before treatment. The ratio of FEV1 / FEV1 occupied capacity and maximal expiratory flow were significantly higher than those before treatment, and the variation rate of maximal expiratory flow was significantly lower than that before treatment.All the indexes in the observation group were significantly better than those in the control group, the difference was statistically significant (P 0.05), the acute asthma attack frequency of the two groups was significantly lower than that of the control group at 1 and 6 months after treatment, and the number of attack in the observation group was significantly lower than that in the control group in the same period.The difference was statistically significant (P 0.05).The incidence of adverse reactions in the observation group was 20.00 and there was no significant difference between the observation group and the control group (14.55%) (P 0.05).Conclusion: tiotropium bromide combined with budesonide formoterol in the treatment of adult severe bronchial asthma can effectively reduce the severity of the disease, improve the respiratory function of patients, reduce the number of acute attacks of asthma, clinical efficacy and high safety.
【作者单位】：海南医学院第一附属医院呼吸内科;
【分类号】：R562.25

【相似文献】